BioArctic (BIOA B.ST) Stock Price
BioArctic Price
Revenue has compounded at 47.3% per year over the past 10 years to 2.00 B SEK. Earnings per share have grown at 75.5% per year over the last 10 years. BioArctic's net margin stands at 51.1%, up from -517.5% several years earlier. BioArctic currently offers a dividend yield of about 0.49%. The payout ratio is around 149% of earnings. Analysts set a median price target of 345.27 SEK, implying 12.4% above the current price. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus.
BioArctic stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
BioArctic business model & stock analysis
Frequently asked questions about BioArctic
The business model of BioArctic AB revolves around developing innovative therapies for debilitating neurological disorders. The company specializes in researching, developing, and commercializing drugs based on antibodies and small molecules. BioArctic AB primarily focuses on addressing neurodegenerative diseases like Alzheimer's and Parkinson's by developing disease-modifying treatments. With a strong emphasis on scientific expertise and collaboration with academic institutions, the company aims to bring novel therapies to market that can improve the quality of life for patients and their families. As a result, BioArctic AB is dedicated to driving advancements in neurodegenerative disease research and providing effective treatment options for those in need.
BioArctic AB is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of BioArctic AB in the market include companies such as Biogen Inc., Eli Lilly and Company, and AbbVie Inc. These companies operate in the biopharmaceutical industry and have a similar focus on developing treatments for neurological disorders like Alzheimer's disease, where BioArctic AB specializes. These competitors have their own portfolios of potential drug candidates and are actively engaged in research and development efforts. However, BioArctic AB distinguishes itself through its innovative approaches and collaborations with other pharmaceutical companies, which contribute to its unique position in the market.
BioArctic AB is a Swedish biopharmaceutical company specializing in the research and development of innovative treatments for neurological disorders. Established in 2003, BioArctic has grown into a leading player in the industry, focusing on diseases such as Alzheimer's and Parkinson's. With a strong commitment to enhancing the quality of life for patients, BioArctic combines cutting-edge science and technology to develop novel therapies. The company has an extensive portfolio of proprietary technologies and partnerships with prominent pharmaceutical companies. BioArctic's dedication to advancing neuroscience and delivering life-changing solutions has positioned it as a key player in the field of neurological research and development.
BioArctic AB has achieved several significant milestones. The company successfully developed and received regulatory approvals for its innovative drug candidate, Aduhelm, for the treatment of Alzheimer's disease. In addition, BioArctic AB entered into collaboration agreements with major pharmaceutical companies, such as Eisai and AbbVie, to further advance its product pipeline. The company also achieved positive clinical trial results for its Parkinson's disease drug candidate, BAN2401. Furthermore, BioArctic AB successfully listed on the Nasdaq Stockholm stock exchange, further enhancing its visibility and access to capital markets. These achievements highlight BioArctic AB's commitment to advancing groundbreaking therapies and its strong position in the biopharmaceutical industry.
BioArctic AB is primarily present in Sweden, where its headquarters are located. The company has a significant presence in the Nordic region, including Norway, Denmark, Finland, and Iceland. Additionally, BioArctic AB has expanded its presence globally, with operations and partnerships in various countries and regions. The company's focus on innovative drug development and research has allowed it to establish a strong presence in the biotechnology and pharmaceutical industries on an international scale.
BioArctic AB represents values of innovative research, scientific excellence, and patient-centric approach. With a strong corporate philosophy focused on enhancing the quality of life for patients, BioArctic is dedicated to developing breakthrough treatments for debilitating disorders. By combining expertise in neuroscience and antibody technologies, BioArctic aims to create novel therapeutics and diagnostics for diseases like Alzheimer's and Parkinson's. The company prioritizes integrity, collaboration, and ethical conduct, striving to make a positive impact on society. BioArctic's commitment to scientific advancement and improving patients' well-being has cemented its position as a leading player in the field of biotechnology.
Analysts currently set an average price target of 326.27 SEK for the BioArctic stock (median: 345.27 SEK), implying +6.2 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the BioArctic stock: 9 recommend buying, 1 holding and 1 selling. For 2026, analysts expect BioArctic to generate revenue of 1.54 B SEK and earnings per share of 5.74 SEK.
Converted at the current exchange rate, the BioArctic share trades at 27.86 EUR (307.20 SEK).
The BioArctic share (BIOA B.ST) is listed on 7 stock exchanges, including: London (0RV2.L), Frankfurt (B9A.F), München (B9A.MU), Düsseldorf (B9A.DU), Stockholm (BIOA B.ST).
BioArctic AB is a Swedish biotechnology company specializing in the development of therapeutics for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company was founded in 2003 and is headquartered in Stockholm, Sweden. The business model of BioArctic is based on three main areas: 1. Product development BioArctic is working on developing new and innovative therapeutic solutions for neurodegenerative diseases. The company collaborates closely with leading scientists and experts in the field to develop new inhibitors and antibodies that can protect the nervous system and stop degenerative processes. An important part of BioArctic's product development process is the clinical phase. The company conducts clinical trials on patients to test the effectiveness of these therapeutics and ensure their safety. 2. Licensing and partnerships BioArctic is also active in the licensing and partnerships space. The company collaborates with other biotechnology or pharmaceutical companies that have an interest in its technologies and products. This allows BioArctic to share its research and development costs and expand its reach in the market. Through partnerships with other companies, BioArctic can also gain access to exclusive technologies and know-how that complement its own capabilities and increase its competitiveness. 3. Licensing out In addition to partnering and collaborating with other companies, BioArctic also licenses its own technologies and products to other companies. The company has already licensed its technology to several companies in the United States, Europe, and Asia. BioArctic's products are highly innovative and unique. The company's flagship product is Aduhelm, an antibody against beta-amyloid plaques that accumulate in the brain and can lead to Alzheimer's disease. Aduhelm was approved by the U.S. Food and Drug Administration (FDA) in June 2021 for the treatment of Alzheimer's disease. BioArctic receives a licensing fee and/or royalties for the use of its technology and the commercial exploitation of the product by the licensed companies. In addition to Aduhelm, BioArctic is also developing other innovative therapeutics such as BAN0805, which aims to degrade alpha-synuclein in the brain fluid. These products are still in development and require further clinical trials before they can be brought to market. In conclusion, BioArctic AB has a successful business model that focuses on the development and commercialization of therapeutic solutions for neurodegenerative diseases. The company collaborates closely with leading scientists and experts in the field to develop innovative products. BioArctic also leverages licensing and partnership agreements to acquire new technologies and capabilities and place its products in the market. The FDA approval of Aduhelm in 2021 has demonstrated BioArctic's potential, with the hope that the company's technology will bring further therapies to the market in the future.
The expected revenue of BioArctic is 1.54 B SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BioArctic is 507.17 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BioArctic is currently 53.47. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioArctic stock.
The price-to-sales ratio (P/S) of BioArctic is currently 17.56. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioArctic stock.
The Eulerpool Quality Score for BioArctic is 7/10.
The ISIN of BioArctic is SE0010323311. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BioArctic is A2H5GS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BioArctic is BIOA B.ST. The ticker symbol is used to trade BioArctic shares on the stock exchange.
BioArctic stock
BioArctic Peer Group
BioArctic Ticker
BioArctic FIGI
All fundamentals and in-depth analysis of BioArctic
Our stock analysis for BioArctic stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioArctic. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.